184 related articles for article (PubMed ID: 38207022)
1. Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape.
Sharma P; Zhang X; Ly K; Kim JH; Wan Q; Kim J; Lou M; Kain L; Teyton L; Winau F
Science; 2024 Jan; 383(6679):190-200. PubMed ID: 38207022
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycosylation of prosaposin in tumor DCs promotes immune escape in cancer.
Sharma P; Zhang X; Ly K; Kim JH; Wan Q; Kim J; Lou M; Kain L; Teyton L; Winau F
bioRxiv; 2023 Jun; ():. PubMed ID: 37398287
[TBL] [Abstract][Full Text] [Related]
3. Prosaposin, tumor-secreted protein, promotes pancreatic cancer progression by decreasing tumor-infiltrating lymphocytes.
Miyahara Y; Takano S; Sogawa K; Tomizawa S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
Cancer Sci; 2022 Aug; 113(8):2548-2559. PubMed ID: 35633503
[TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy.
Zhu S; Yang N; Wu J; Wang X; Wang W; Liu YJ; Chen J
Pharmacol Res; 2020 Sep; 159():104980. PubMed ID: 32504832
[TBL] [Abstract][Full Text] [Related]
5. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment.
Fu C; Jiang A
Front Immunol; 2018; 9():3059. PubMed ID: 30619378
[TBL] [Abstract][Full Text] [Related]
6. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
7. Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.
DeVito NC; Plebanek MP; Theivanthiran B; Hanks BA
Front Immunol; 2019; 10():2876. PubMed ID: 31921140
[TBL] [Abstract][Full Text] [Related]
8. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.
Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW
Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156
[TBL] [Abstract][Full Text] [Related]
9. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
10. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cell: a protection for tumour cells.
Wang Y; Ma Y; Fang Y; Wu S; Liu L; Fu D; Shen X
J Cell Mol Med; 2012 Mar; 16(3):425-36. PubMed ID: 21895966
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
14. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
15. Type I interferon activates MHC class I-dressed CD11b
Duong E; Fessenden TB; Lutz E; Dinter T; Yim L; Blatt S; Bhutkar A; Wittrup KD; Spranger S
Immunity; 2022 Feb; 55(2):308-323.e9. PubMed ID: 34800368
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade.
Hübbe ML; Jæhger DE; Andresen TL; Andersen MH
Front Immunol; 2020; 11():578349. PubMed ID: 33101304
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
20. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
